Mind Medicine Mindmed Inc (MNMD)
$6.31
0.23 (3.78%)
MNMD Stock Quote Delayed 30 Minutes
10 Penny Stocks to Buy to Create a $500 Portfolio
These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
645,175
Day's Range
$6.09 - $6.48
52-Week Range
$2.41 - $12.22
Dividend & Yield
N/A (N/A)
MNMD Stock Predictions, Articles, and Mind Medicine Mindmed Inc News
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
MindMed Stock Is Overvalued and Too Risky to Own
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments.
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
MNMD stock is positioned for long-term growth as its LSD, MDMA, and Psilocybin-based treatments have a huge addressable mental wellness market.
Mind Medicine Stock Might Still Be Worth the Risk Here
While MNMD stock is incredibly speculative due to uncertainties of psychedelic therapeutics, the need may transcend the risks.
The Mind Medicine Stock Story Has an Awful Lot of Holes in It
MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time
Mind Medicine Stock Is Not a Trip To Take Just Yet
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
The Jury’s Still Out on Psychedelics Play MindMed Stock
It has a shot of finding success. Yet, said success remains many years away. In the meantime, those who bought in for fast gains may get impatient, sending shares back down to lower prices. With this in mind, the best move with MNMD stock in the near-term may be to tread carefully.
Strong Cash Balance Should Provide a Foundation for MindMed Stock
Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on Bitcoin prices, EV stocks and hype in the psychedelics market.
MNMD Stock: The Big News That Has MindMed Investors Psyched Today
MindMed (MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week right with a collection of the biggest pre-market stock movers for Monday that investors need to know about.
